Bristol Myers Squibb’s Breyanzi Granted Regulatory Acceptance in the U.S. and Japan for Relapsed or Refractory Follicular Lymphoma and Relapsed or Refractory Mantle Cell Lymphoma
Bristol Myers Squibb (NYSE: BMY) has received regulatory acceptance from both the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) for Breyanzi® (lisocabtagene…
Sanofi Achieves Robust Sales and Business EPS Growth at Constant Exchange Rates, Fueled by Successful Product Launches and Progress in Immunology Pipeline
In Q4 2023, Sanofi experienced a robust sales growth of 9.3% at Constant Exchange Rates (CER) and an 8.2% increase in business EPS. Notable achievements include Specialty Care’s 13.7% growth…
Priority Review Granted in the US for Enhertu in Patients with Metastatic HER2-Positive Solid Tumors
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review by the US Food and Drug Administration (FDA) for the…
Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO) Demonstrated by Roche’s Vabysmo
Roche (SIX: RO, ROG; OTCQX: RHHBY) has disclosed compelling 72-week data derived from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in the treatment of macular edema…
Novo Nordisk’s sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023
Novo Nordisk’s sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023 PROFIT AND LOSS 2023 2022 Growthas reported Growthat…
EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRAHIGH-DOSE FORMULATION IN JAPAN FOR THE INDICATION OF AMYOTROPHIC LATERAL SCLEROSIS
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of…
Notice of Investment Agreement with Niremia Collective
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have concluded investment agreement with Niremia Collective, a venture capital firm specializing…
ObjectiveHealth Announces Strategic Growth Investment from Vitruvian Partners
ObjectiveHealth, a leading integrated specialty research network and technology company, announced today that it has secured a strategic growth investment from Vitruvian Partners, a leading global growth-focused investment firm. ObjectiveHealth…
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
Lonza has reported sales of CHF 6.7 billion, sales growth of 7.9% AER2 (10.9%1 CER), and CHF 2 billion CORE EBITDA, resulting in a margin of 29.8%. The solid financial results were…
Merck and China Resources Power Enter into Long-Term Green Power Agreement to Reduce Carbon Footprint in China
Merck, a leading science and technology company, has signed a 10-year green power purchase agreement (PPA) with China Resources Power Holdings Co., Ltd. This is Merck’s first long-term renewable energy…
The Ohio State University Wexner Medical Center and CVS Accountable Care collaborate to improve Medicare beneficiary care coordination in Ohio
The Ohio State University Wexner Medical Center and CVS Accountable Care, part of CVS Health® (NYSE: CVS), today announced the creation of an accountable care organization (ACO) to improve the quality of care…
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization approval of Abecma® (idecabtagene vicleucel; ide-cel) for…